Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

Metformin is one of the most widely prescribed hypoglycemic drugs and has the potential to
treat many diseases. More and more evidence shows that metformin can regulate the …

SGLT2 inhibitors offer strong renoprotection in subjects with diabetic kidney disease (DKD).
But the mechanism for such protection is not clear. Here, we report that in damaged proximal …

Aberrant proliferation of vascular smooth muscle cells (VSMC) is a critical contributor to the
pathogenesis of atherosclerosis (AS). Our previous studies have demonstrated that apelin …

Management guidelines continue to identify metformin as initial pharmacologic antidiabetic
therapy of choice for people with type 2 diabetes without contraindications, despite recent …

Background and Purpose: Atherosclerosis is the main pathophysiological foundation of
cardiovascular disease, which was caused by inflammation and lipid metabolism disorder …

The development and application of traditional drugs represented by small molecule
chemical drugs and biological agents, especially inhibitors, have become the mainstream …

Background and Purpose: Atherosclerosis is an underlying cause of coronary heart disease.
Foam cell, a hallmark of atherosclerosis, is prominently derived from monocyte-differentiated …

Non-alcoholic fatty liver disease (NAFLD) is currently among the most common liver
diseases. Unfavorable data on the epidemiology of metabolic syndrome and obesity have …

Diabetic nephropathy (DN), a kind of microvascular complication, is a primary cause of end-
stage renal disease worldwide. However, therapeutic drugs for DN treatment are still in lack …